Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mamta Garg

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Blood|November 14, 2023
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinibAlex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, et al.
Haematologica|June 6, 2020
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized TrialClaire N Harrison, Jyoti Nangalia, Rebecca Boucher, et al.
American Journal of Hematology|March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaHolger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
British Journal of Haematology|May 3, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United KingdomAlexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, et al.
Journal of Hematology & Oncology|April 14, 2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaMaria V Mateos, Maria Gavriatopoulou, Thierry Facon, et al.
American Journal of Hematology|June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic riskShambavi Richard, Ajai Chari, Sosana Delimpasi, et al.
The Lancet. Oncology|July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trialVania Hungria, Paweł Robak, Marek Hus, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaVania Hungria, Pawel Robak, Marek Hus, et al.
Lancet (London, England)|November 15, 2020
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trialSebastian Grosicki, Maryana Simonova, Ivan Spicka, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Blood|November 14, 2023
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinibAlex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, et al.
Haematologica|June 6, 2020
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized TrialClaire N Harrison, Jyoti Nangalia, Rebecca Boucher, et al.
American Journal of Hematology|March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaHolger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
British Journal of Haematology|May 3, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United KingdomAlexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, et al.
Journal of Hematology & Oncology|April 14, 2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaMaria V Mateos, Maria Gavriatopoulou, Thierry Facon, et al.
American Journal of Hematology|June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic riskShambavi Richard, Ajai Chari, Sosana Delimpasi, et al.
The Lancet. Oncology|July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trialVania Hungria, Paweł Robak, Marek Hus, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaVania Hungria, Pawel Robak, Marek Hus, et al.
Lancet (London, England)|November 15, 2020
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trialSebastian Grosicki, Maryana Simonova, Ivan Spicka, et al.
Pageof 5